Company profile: Treos Bio
1.1 - Company Overview
Company description
- Provider of computational immunology solutions that predict in silico likely responders to cancer immunotherapies and design next-generation targeted immunotherapies tailored to patient genetics; offers PolyPEPI1018 for metastatic colorectal cancer (developed without need for tumor biopsy), PEPI Panel to create personalized therapies based on tumor type and HLA genotype, PolyPEPI-SCoV-2 preventive vaccine, and PEPI Test predicting peptide-specific T cell responses.
Products and services
- PEPI Panel: Custom-engineered library of immunogenic peptide fragments used to assemble personalized cancer products by matching a patient’s tumor type and HLA genotype
- PEPI Test: Computational-grade diagnostic that predicts peptide-specific T cell responses from an individual’s HLA genotype and is used alongside PolyPEPI immunotherapies
- PolyPEPI1018: Peptide-based cancer immunotherapy engineered to treat metastatic colorectal cancer, developed without the need for tumor biopsy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Treos Bio
GeneDx
HQ: United States
Website
- Description: Provider of genomic diagnostics and data science solutions using artificial intelligence and machine learning to deliver personalized, actionable insights that improve health outcomes. Offers XomeDxXpress rapid whole exome sequencing (provisional results in 7 days, full report in 2 weeks), whole genome sequencing with optional trio testing, and genetic counseling services for patients and healthcare providers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneDx company profile →
Catalog
HQ: United States
Website
- Description: Provider of a data conversion and storage platform used to offer next-generation digital data archives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Catalog company profile →
DNA Diagnostics Center
HQ: United States
Website
- Description: Provider of paternity and other DNA testing services, including prenatal paternity, ancestry, forensic (for legal and criminal investigations), siblingship, and grandparentage testing. Founded in 1995 and based in Fairfield, Ohio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Diagnostics Center company profile →
Firefly BioWorks
HQ: United States
Website
- Description: Provider of an open platform that enables industrial, academic, and clinical scientists to develop and use multiplexed biological assays on standard laboratory instrumentation, leveraging its core Optical Liquid Stamping technology developed in MIT’s Chemical Engineering Department.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Firefly BioWorks company profile →
BISC Global
HQ: Belgium
Website
- Description: Provider of bioinformatics, statistics, and machine learning consulting, helping customers overcome challenges in data analysis, pipeline automation, visualization, and compute environments. Consultants work on-site or off-site, project-based or time-based, with a strong focus on communication and deliverables.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BISC Global company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Treos Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Treos Bio
2.2 - Growth funds investing in similar companies to Treos Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Treos Bio
4.2 - Public trading comparable groups for Treos Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →